Lomedeucitinib

DB21649InvestigationalSmall molecule

Lomedeucitinib is a small molecule drug. The usage of the INN stem '-citinib' in the name indicates that Lomedeucitinib is a Janus kinase inhibitor. Lomedeucitinib is under investigation in clinical... Lomedeucitinib is under investigation in clinical trial NCT05730725 (A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis).

Formula / weight: C₁₈H₂₀N₆O₄S · 419.47 g/mol (avg)
Code names: BMS-986322 · BMS-986322-01

Resolves to

Compound

UNIIEYQ7KA55XACAS2328068-29-5ChEMBLCHEMBL5314608ChEBI759305PubChem138620496

Structure

InChIKeyVWIVBQZLVAGLMH-ASGODXDTSA-NSMILES[2H]C([2H])([2H])NC(=O)C1=C(NC2=C(C=CC=N2)S(C)(=O)=O)C=C(NC(=O)[C@@H]2CC22CC2)N=N1

What you can answer from here — as of September 23, 2026

4Clinical trialsPhase, status and sponsor resolved per trial

Which companies are running trials of Lomedeucitinib, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account